Table 1. Reported trials of neoadjuvant and adjuvant therapy.
| Trials | Delete column, use ref # | Study design | Stage and/or pathologic type | NAd | Ad | N | 2-year DFS | Median DFS | 2-year OS | Median OS |
|---|---|---|---|---|---|---|---|---|---|---|
| Gold KA ￥ | WCLC | II | Stage IB-III NSCLC | DOC + DDP ×3 cycles | Erlotinib ×1 year | 46 | ||||
| Rizvi NA | Clin Cancer Res | II | Stage I or II NSCLC (T1-2 N0-1 or T3N0M0); adenocarcinoma | Gefitinib ×21 days | Gefitinib ×2 years (EGFR mutation+ or with effective neoadjuvant therapy) | 21 | 95% | NR | ||
| None (patients without effective neoadjuvant therapy) | 29 | 78% | NR | |||||||
| Janjigian YY | JTO | Re | Stage I-III; adenocarcinoma with EGFR 19 or 21 exon mutations | 21 cases: Gefitinib ×21 days | G/E (median medication time: 24 months) | 56 | 89% | 96% | ||
| None | 111 | 72% | 90% | |||||||
| D’Angelo SP | JTO | Re | Stage I-III NSCLC; adenocarcinoma with 19-exon and 21-exon (L858R) mutation @@ | G/E neoadjuvant therapy | G/E ×2 years | 84@ | ||||
| ×21 days | ||||||||||
| Waterhouse DM## | ASCO7035 | II | Staging IB-IIIA* NSCLC, any pathological types | None | CBP (AUC =5) + DOC + BEV day 1, q21d ×4 cycles; then BEV day 1 + E q21d ×8 cycles | 54 | 1-year DFS: 78% | 2-year DFS: 77.6% | 3-year OS: 81% | |
| None | CBP (AUC =5) + DOC day 1, q21d ×4 cycles | 52 | 88% | 86.80% | 63% | |||||
| BR19 | JCO | III | Staging IB/II/IIIA NSCLC | None | G ×2 years | 251 | 4.2 years | 5.1 years | ||
| None | Placebo ×2 years | 252 | NR | NR | ||||||
| Wang SY | ASCO | II | Staging IIIA-N2 NSCLC; (19-exon deficiency or L858R point-mutation) | None | PEM + CBP (AUC =5) q3w ×4 cycles; then G, 6 months | 30 | 78.90% | 39.8 months | 92.40% | 41.6 months |
| 7519 | None | PEM + CBP (AUC =5) q3w ×4 cycles; without G | 30 | 54.20% | 27.0 months | 77.40% | 32.6 months | |||
| Waterhouse | II | Randomized | Maintenance treatment | |||||||
| Arm A: BEV + erlotinib, q21d ×8 cycles | 54 | 1-year DFS: 78% | 3-year OS: 81% | |||||||
| Arm B: CBP (AUC5) + DOC, q3w ×4 cycles | 52 | 88% | 63% | |||||||
| Induction treatment: CBP AUC5, DOC, BEV, q21d ×4 cycles | ||||||||||
#, adjusted for factors such as gender, pathological staging, surgery type, and adjuvant platinum-based therapy, HR <1 suggesting an improved quality of life; ￥, remission rate after inductive chemotherapy. Toxicity database reported without survival data (the meaning of this text is unclear); @, of EGFR mutation+ patients, 53 (24%) underwent adjuvant TKI therapy, 19 (9%) underwent TKI therapy only when disease recurred, 11 (5%) underwent TKI adjuvant therapy and experienced recurrence; @@, platinum-based therapy ×4 weeks and/or radiotherapy IIIA-N2; ##, analysis of the 2-year DFS data. OS according to stage; and without summarized OS and DFS data (the meaning of this text is unclear); *, primary endpoint: the relationship between imaging remission of gefitinib (on day 21: shrinkage by at least 25% via two-dimensional measurement) and EGFR mutation. NAd, neoadjuvant therapy; Ad, adjuvant therapy; DFS, disease-free survival; OS, overall survival; NSCLC, non-small cell lung cancer; DOC, docetaxel; DDP, diamminedichloroplatinum; EGFR, epidermal growth factor receptor; NR, not reported; JTO, Journal of Thoracic Oncology; G/E, gefitinib or erlotinib; ASCO, American Society of Clinical Oncology; CBP, carboplatin; AUC, area under the curve; BEV, bevacizumab; JCO, Journal of Clinical Oncology; PEM, pemetrexed; TKI, tyrosine kinase inhibitor; Re, retrospective.